MenHibrix: A New Combination Meningococcal Vaccine for Infants and Toddlers

Annals of Pharmacotherapy

Volumn 48, Issue 3, 2014, Pages 404-411

  Hale, Sarah F ^a   Camaione, Lauren ^b   Lomaestro, Ben M ^c  

^a GEISINGER HEALTH SYSTEM   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c ALBANY MEDICAL CENTER   (United States)

Author keywords

Haemophilus influenzae type b Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine; Hib MenCY TT; immunization; MenHibrix; vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B NEISSERIA MENINGITIDIS SEROGROUPS C AND Y TETANUS TOXOID CONJUGATE VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MENHIBRIX; MENINGOCOCCUS VACCINE; MENOMUNEMENOMUNE; TETANUS TOXOID; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANEMIA; ANTIBODY RESPONSE; ANTIBODY TITER; CONJUGATE; DELTOID MUSCLE; DROWSINESS; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; FOLLOW UP; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; HYPOTONIC HYPORESPONSIVE EPISODE; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA; INJECTION PAIN; INJECTION SITE SWELLING; IRRITABILITY; LOSS OF APPETITE; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; PERSONALITY DISORDER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SERUM BACTERICIDAL ACTIVITY; SKIN REDNESS; TETANUS; TETANUS PROPHYLAXIS; TODDLER; TREATMENT DURATION; VACCINATION; VIRAL GASTROENTERITIS;

HAEMOPHILUS INFLUENZAE TYPE B-NEISSERIA MENINGITIDIS SEROGROUPS C AND Y TETANUS TOXOID CONJUGATE VACCINE; HIB-MENCY-TT; IMMUNIZATION; MENHIBRIX; VACCINE;

CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; HAEMOPHILUS VACCINES; HUMANS; INFANT; MENINGITIS, HAEMOPHILUS; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; POLYSACCHARIDES, BACTERIAL; TETANUS TOXOID; VACCINATION; VACCINES, CONJUGATE;

EID: 84896810456     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028013514375     Document Type: Review

References (32)

1. Harrison LH.Epidemiological profile of meningococcal disease in the United States.Clin Infect Dis. 2010;50:S37-S44.
2. Cohn AC,MacNeil JR,Harrison LH,et al.Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease.Clin Infect Dis. 2010;50:184-191.
3. Centers for Disease Control and Prevention. Meningococcal disease. http://www.cdc.gov/meningococcal/clinical-info.html. Accessed March 15, 2012.
4. Red Book: 2012 Report of the Committee on Infectious Disease. 2012 Report of the Committee on Infectious Disease. 29th ed.Elk Grove Village, IL: American Academy of Pediatrics; 2012:500-509.Pickering LKBaker CJKimberlin DWLong SS, ed. Elk Grove Village, IL: American Academy of Pediatrics; 500-509.
5. Centers for Disease Control and Prevention. Haemophilus influenzae disease (including Hib). http://www.cdc.gov/hi-disease/clinicians.html. Accessed March 15, 2012.
6. Research Triangle Park, NC: GlaxoSmithKline; 2012:.
7. Bryant KA,Marshall GS.Haemophilus influenza type b-Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine for infants and toddlers.Expert Rev Vaccines. 2011;10:941-950.
8. Poland GA.Prevention of meningococcal disease: current use of polysaccharide and conjugate vaccines.Clin Infect Dis. 2010;50:S45-S53.
9. Food and Drug Administration. August1, 2013approval letter: Menveo. http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm363785.htm. Accessed August 25, 2013.
10. Cohn AC,Harrison LH.Meningococcal vaccines: current issues and future strategies.Drugs. 2013;73:1147-1155.
11. Nadel S.Prospects for eradication of meningococcal disease.Arch Dis Child. 2012;97:993-998.
12. Goldblatt D.Conjugate vaccines.Clin Exp Immunol. 2000;119:1-3.
13. Food and Drug Administration. Clinical review of biologics license application for GlaxoSmithKline Biologicals' meningococcal C and Y and Haemophilus b conjugate vaccine. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM315680.pdf. Accessed March 15, 2012.
14. Goldschneider I,Gotschlich EC,Artenstein MS.Human immunity to the meningococcus: I. The role of humoral antibodies.J Exp Med. 1969;129:1307-1326.
15. Peltola H,Käyhty H,Sivonen A,Mäkelä PH.Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland.Pediatrics. 1977;60:730-737.
16. Robbins JB,Parke JC,Schneerson R,Whisnant JK.Quantitative measurement of "natural" and immunization-induced Haemophilus influenzae type b capsular polysaccharide antibodies.Pediatr Res. 1973;7:103-110.
17. Ambrosino DM,Landesman SH,Gorham CC,Siber GR.Passive immunization against disease due to Haemophilus influenzae type b: concentrations of antibody to capsular polysaccharide in high-risk children.J Infect Dis. 1986;153:1-7.
18. Anderson P.The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b.J Infect Dis. 1984;149:1034-1035.
19. Käyhty H,Peltola H,Karanko V,Mäkelä PH.The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b.J Infect Dis. 1983 1100;147:.
20. Perry CM.Meningococcal groups C and Y and Haemophilus b tetanus toxoid conjugate vaccine (HibMenCY-TT; MenHibrix®): a review.Drugs. 2013;73:703-713.
21. Bryant KA,Marshall GS,Marchant CD,et al.Immunogenicity and safety of H influenzae type b-N meningitidis C/Y conjugate vaccine in infants.Pediatrics. 2011;127:e1375-e1385.
22. Marshall GS,Marchant CD,Blatter M,et al.Immune response and one-year antibody persistence after a fourth dose of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY) at 12 to 15 months of age.Pediatr Infect Dis J. 2010;29:469-471.
23. Marshall GS,Blatter M,Marchant C,Aris E,Mesaros N,Miller JM.Antibody persistence for up to 5 years after a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (Hibmency-TT) given at 12-15 months of age.Pediatr Infect Dis J. 2013;32:662-668.
24. Habermehl P,Leroux-Roels G,Sanger R,Machler G,Boutriau D.Combined Haemophilus influenzae type b and Neisseria meningitidis serogroups C (HibMenC) or serogroups C and Y-tetanus toxoid conjugate (and HibMenCY) vaccines are well-tolerated and immunogenic when administered according to the 2,3,4 months scheduled with a fourth dose at 12-18 months of age.Hum Vaccin. 2010;6:640-651.
25. Marchant CD,Miller JM,Marshall GS,et al.Randomized trial to assess immunogenicity and safety of Haemophilus influenza type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants.Pediatr Infect Dis J. 2010;29:48-52.
26. Nolan T,Lambert S,Roberton D,et al.A novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus-toxoid conjugate vaccine is immunogenic and induces immune memory when co-administered with DTPa-HBV-IPV and conjugate pneumococcal vaccines in infants.Vaccine. 2007;25:8487-8499.
27. Nolan T,Richmond P,Marshall H,et al.Immunogenicity and safety of an investigational combined Haemophilus influenzae type B-Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine.Pediatr Infect Dis J. 2011;30:190-196.
28. Rinderknecht S,Bryant K,Nolan T,et al.The safety profile of Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine (HibMenCY).Hum Vaccin Immunother. 2012;8:304-311.
29. Bryant K,Marshall GS,Marchant CD,et al.Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine (HibMenCY) was immunogenic with an acceptable safety profile in two Phase 3 trials (abstract no. 22739).Programs and Abstracts of the 44th National Immunization Conference.
30. Marshall GS,Marchant CD,Blatter M,Friedland LR,Aris E,Miller JM.Co-administration of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine does not interfere with the immune response to antigens contained in infant vaccines routinely used in the United States.Hum Vaccin. 2011;7:258-264.
31. Bryant KA,McVernon J,Marchant CD,et al.Immunogenicity and safety of measles-mumps-rubella and varicella vaccines coadministered with a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in toddlers.Hum Vaccin Immunother. 2012;8:1036-1041.
32. Infant meningococcal vaccination: advisory committee on immunization practices (ACIP) recommendations and rationale.Morb Mort Wkly Rep. 2013;62:52-54.